Jun. 26 at 12:26 PM
$ZVSA ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)
By ZyVersa Therapeutics | June 26, 2025, 7:55 AM